Komori
Mitani Sangyo (8285) · RiskFirst stated

Temporary Increase in Cost of Sales Due to Bringing Forward Validation of a New Active Pharmaceutical Ingredient

First written in FY2018-Q2. . Latest entry: FY2018-Q2.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Temporary cost increase from accelerated validation of new active pharmaceutical ingredientsA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2018-Q2First statedAnnual report

    「Costs temporarily increased as validation was brought forward to accelerate the development of new active pharmaceutical ingredient products for pharmaceuticals, resulting in ¥644 million, down 0.2% year on year.」

    The temporary increase in costs associated with bringing forward validation actually occurred, causing operating income in the chemicals-related business to decline 0.2% year on year.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Mitani Sangyo's next results are scheduled for 2026-10-30. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Temporary Increase in Cost of Sales Due to Bringing Forward Validation of a New Active Pharmaceutical Ingredient | MITANI SANGYO CO.,LTD. (8285) | Komori